2023
KRAS mutation in primary ovarian serous borderline tumors correlates with tumor recurrence
McHenry A, Rottmann D, Buza N, Hui P. KRAS mutation in primary ovarian serous borderline tumors correlates with tumor recurrence. Virchows Archiv 2023, 483: 71-79. PMID: 37219599, DOI: 10.1007/s00428-023-03564-z.Peer-Reviewed Original ResearchConceptsOvarian serous borderline tumorsSerous borderline tumorsNon-invasive implantsDisease-free survivalKRAS mutationsTumor recurrenceExtraovarian implantsAdverse disease-free survivalWorse disease-free survivalHigher stage diseaseKRAS mutation testingHigher tumor stageWild-type KRASBRAF V600E mutationBRAF mutational analysisBorderline tumorsClinical outcomesHistological subtypesTumor stageBRAF mutationsUseful biomarkerInvasive implantsTumors correlatesV600E mutationMutational status
2020
HER2 Testing in Endometrial Serous Carcinoma: Time for Standardized Pathology Practice to Meet the Clinical Demand
Buza N. HER2 Testing in Endometrial Serous Carcinoma: Time for Standardized Pathology Practice to Meet the Clinical Demand. Archives Of Pathology & Laboratory Medicine 2020, 145: 687-691. PMID: 32649220, DOI: 10.5858/arpa.2020-0207-ra.Peer-Reviewed Original ResearchConceptsEndometrial serous carcinomaSerous carcinomaHER2 protein expressionHER2 testingNational Comprehensive Cancer Network clinical guidelinesProlonged progression-free survivalHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Gene amplificationStandard chemotherapy regimenProgression-free survivalProtein expressionAppropriate patient selectionGrowth factor receptor 2Recent clinical trialsSuccessful clinical outcomeHER2 protein overexpressionFactor receptor 2HER2 scoring criteriaHER2 therapyChemotherapy regimenEndometrial cancerClinical outcomesPatient selectionAggressive subtype